Home / Pharma News / Medicure and Reliance sign cardiovascular drug agreement
Medicure and Reliance sign cardiovascular drug agreement Posted 30/10/2020

Medicure Inc announced on 5 October 2020 that it has entered a License, Manufacture and Supply Agreement with Reliance Life Sciences Private Limited (RLS) for a cardiovascular drug. Under this agreement, Medicure is responsible for the regulatory approval process for the drug product and is granted the exclusive right to market and sell it in Canada, European Union and the US. The cardiovascular drug is currently unnamed.
Medicure is a Canadian company that specializes in the development and commercialization of cardiovascular therapies. Two of its current products are tirofiban hydrochloride (Aggrastat), an anticoagulant, and pitavastatin (Zypitamag), a cholesterol-lowering statin. RLS is a diverse pharmaceuticals company with a focus on biotherapeutics, including biosimilars, regenerative medicine, pharmaceuticals, clinical research services and molecular medicine. RLS has developed a variety of similar biologics and those approved in India include filgrastim in 2008 [1], rituximab in 2015 [2] and bevacizumab in 2016 [3]. However, RLS’s epoetin alfa biosimilar application in Europe was withdrawn in 2011 [4]. Medicure focusses specifically on the US market, while its new Indian collaborator, RLS does not currently have any biosimilar products with FDA approval. The companies are combining their expertise to bring the cardiovascular drug to market in the US and other regions.
Related article
References Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing. Copyright – Unless otherwise stated all contents of this website are © 2020 Pro Pharma Communications International. All Rights Reserved.
Torrent licenses three ‘similar biologics’ from Reliance
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of filgrastim [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Oct 30]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-filgrastim
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of rituximab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Oct 30]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-rituximab
3. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of bevacizumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Oct 30]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-bevacizumab
4. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Europe [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Oct 30]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe
Comments (0)
Generics News Research General
- The role of authorized generics in Improving a...Generics/Research | Posted 05/03/2021
- Opportunities for generics with Korean patent e...Generics/General | Posted 05/03/2021
- Approving generics of polymer-based parenteral...Generics/Research | Posted 26/02/2021
- AIFA updates the Transparency Lists for genericsGenerics/General | Posted 26/02/2021
Biosimilars News Research General
- Biosimilar patent litigation trends in the USBiosimilars/General | Posted 05/03/2021
- Biosimilars approved in the USBiosimilars/General | Posted 14/08/2015
- Different approaches to the interchangeability...Biosimilars/Research | Posted 05/03/2021
- Efficacy and safety of interferon beta-1a (Reci...Biosimilars/Research | Posted 05/03/2021